Delivery of an ectonucleotidase inhibitor with ROS-responsive nanoparticles overcomes adenosine-mediated cancer immunosuppression
Published 2022 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Delivery of an ectonucleotidase inhibitor with ROS-responsive nanoparticles overcomes adenosine-mediated cancer immunosuppression
Authors
Keywords
-
Journal
Science Translational Medicine
Volume 14, Issue 648, Pages -
Publisher
American Association for the Advancement of Science (AAAS)
Online
2022-06-09
DOI
10.1126/scitranslmed.abh1261
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- ARC-9: Phase Ib/II study to evaluate etrumadenant (AB928)-based treatment combinations in patients with metastatic colorectal cancer (mCRC).
- (2021) Michael Cecchini et al. JOURNAL OF CLINICAL ONCOLOGY
- CD39 Regulation and Functions in T Cells
- (2021) Eleonora Timperi et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Adoptive cell therapy with tumor-specific Th9 cells induces viral mimicry to eliminate antigen-loss-variant tumor cells
- (2021) Gang Xue et al. CANCER CELL
- Use of ex vivo patient derived tumor organotypic spheroids to identify combination therapies for HER2mutant non small cell lung cancer
- (2020) Elena Ivanova et al. CLINICAL CANCER RESEARCH
- On the mechanism of anti-CD39 immune checkpoint therapy
- (2020) David Allard et al. Journal for ImmunoTherapy of Cancer
- Does heart surgery change the capacity of α1-antitrypsin to inhibit the ATP-induced release of monocytic interleukin-1β? A preliminary study
- (2020) A. Agné et al. INTERNATIONAL IMMUNOPHARMACOLOGY
- A phase I, open-label, multicenter study to assess the safety, pharmacokinetics, and preliminary antitumor activity of AZD4635 both as monotherapy and in combination in patients with advanced solid malignancies: Results from prostate cancer patients (NCT02740985).
- (2020) Emerson A. Lim et al. JOURNAL OF CLINICAL ONCOLOGY
- Cx43 channels and signaling via IP3/Ca2+, ATP, and ROS/NO propagate radiation-induced DNA damage to non-irradiated brain microvascular endothelial cells
- (2020) Delphine Hoorelbeke et al. Cell Death & Disease
- Nucleotide Analog ARL67156 as a Lead Structure for the Development of CD39 and Dual CD39/CD73 Ectonucleotidase Inhibitors
- (2020) Laura Schäkel et al. Frontiers in Pharmacology
- Revisiting the PD-1 pathway
- (2020) Nikolaos Patsoukis et al. Science Advances
- Regulatory T cells in cancer immunosuppression — implications for anticancer therapy
- (2019) Yosuke Togashi et al. Nature Reviews Clinical Oncology
- Co-delivery of Bee Venom Melittin and a Photosensitizer with an Organic–Inorganic Hybrid Nanocarrier for Photodynamic Therapy and Immunotherapy
- (2019) Haojie Liu et al. ACS Nano
- An inhalable nanoparticulate STING agonist synergizes with radiotherapy to confer long-term control of lung metastases
- (2019) Yang Liu et al. Nature Communications
- Adenosine 2A Receptor Blockade as an Immunotherapy for Treatment-Refractory Renal Cell Cancer
- (2019) Lawrence Fong et al. Cancer Discovery
- Targeting CD39 in Cancer Reveals an Extracellular ATP- and Inflammasome-Driven Tumor Immunity
- (2019) Xian-Yang Li et al. Cancer Discovery
- Bioinspired Hybrid Protein Oxygen Nanocarrier Amplified Photodynamic Therapy for Eliciting Anti-tumor Immunity and Abscopal Effect
- (2018) Zhikuan Chen et al. ACS Nano
- Mechanisms of resistance to immune checkpoint inhibitors
- (2018) Russell W Jenkins et al. BRITISH JOURNAL OF CANCER
- Metformin-Induced Reduction of CD39 and CD73 Blocks Myeloid-Derived Suppressor Cell Activity in Patients with Ovarian Cancer
- (2018) Lifeng Li et al. CANCER RESEARCH
- Phase I/II study of the A2AR antagonist NIR178 (PBF-509), an oral immunotherapy, in patients (pts) with advanced NSCLC.
- (2018) Alberto Chiappori et al. JOURNAL OF CLINICAL ONCOLOGY
- Bystander CD8+ T cells are abundant and phenotypically distinct in human tumour infiltrates
- (2018) Yannick Simoni et al. NATURE
- The hallmarks of successful anticancer immunotherapy
- (2018) Lorenzo Galluzzi et al. Science Translational Medicine
- A Paradigm Shift in Cancer Immunotherapy: From Enhancement to Normalization
- (2018) Miguel F. Sanmamed et al. CELL
- Design strategies for chemical-stimuli-responsive programmable nanotherapeutics
- (2018) Muhammad Gulfam et al. DRUG DISCOVERY TODAY
- Entinostat Converts Immune-Resistant Breast and Pancreatic Cancers into Checkpoint-Responsive Tumors by Reprogramming Tumor-Infiltrating MDSCs
- (2018) Brian J. Christmas et al. Cancer Immunology Research
- Ectonucleotidase inhibitors: a patent review (2011-2016)
- (2017) Mariya Al-Rashida et al. EXPERT OPINION ON THERAPEUTIC PATENTS
- The ectonucleotidases CD39 and CD73: Novel checkpoint inhibitor targets
- (2017) Bertrand Allard et al. IMMUNOLOGICAL REVIEWS
- A pathology atlas of the human cancer transcriptome
- (2017) Mathias Uhlen et al. SCIENCE
- Co-inhibition of CD73 and A2AR Adenosine Signaling Improves Anti-tumor Immune Responses
- (2016) Arabella Young et al. CANCER CELL
- Chemotherapy-Induced IL34 Enhances Immunosuppression by Tumor-Associated Macrophages and Mediates Survival of Chemoresistant Lung Cancer Cells
- (2016) M. Baghdadi et al. CANCER RESEARCH
- Immune suppressive mechanisms in the tumor microenvironment
- (2016) David H Munn et al. CURRENT OPINION IN IMMUNOLOGY
- Immunosuppressive activities of adenosine in cancer
- (2016) Bertrand Allard et al. CURRENT OPINION IN PHARMACOLOGY
- 10-Boronic acid substituted camptothecin as prodrug of SN-38
- (2016) Lei Wang et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase 1b trial
- (2016) Tanguy Y Seiwert et al. LANCET ONCOLOGY
- Eradication of large established tumors in mice by combination immunotherapy that engages innate and adaptive immune responses
- (2016) Kelly D Moynihan et al. NATURE MEDICINE
- Enhanced Tumor Control with Combination mTOR and PD-L1 Inhibition in Syngeneic Oral Cavity Cancers
- (2016) E. C. Moore et al. Cancer Immunology Research
- Established T Cell-Inflamed Tumors Rejected after Adaptive Resistance Was Reversed by Combination STING Activation and PD-1 Pathway Blockade
- (2016) E. Moore et al. Cancer Immunology Research
- Regulatory T Cells: Differentiation and Function
- (2016) G. Plitas et al. Cancer Immunology Research
- A Metabolic Immune Checkpoint: Adenosine in Tumor Microenvironment
- (2016) Akio Ohta Frontiers in Immunology
- Fusogenic Reactive Oxygen Species Triggered Charge-Reversal Vector for Effective Gene Delivery
- (2015) Xin Liu et al. ADVANCED MATERIALS
- Tissue-based map of the human proteome
- (2015) M. Uhlen et al. SCIENCE
- The future of immune checkpoint therapy
- (2015) P. Sharma et al. SCIENCE
- A new adjuvant delivery system ‘cyclic di-GMP/YSK05 liposome’ for cancer immunotherapy
- (2014) Hiroko Miyabe et al. JOURNAL OF CONTROLLED RELEASE
- An Activatable Prodrug for the Treatment of Metastatic Tumors
- (2014) Eun-Joong Kim et al. JOURNAL OF THE AMERICAN CHEMICAL SOCIETY
- Inhibition of CD39 Enzymatic Function at the Surface of Tumor Cells Alleviates Their Immunosuppressive Activity
- (2014) J. Bastid et al. Cancer Immunology Research
- Regulation of Inflammation by Adenosine
- (2013) György Haskó et al. Frontiers in Immunology
- Immunogenic Cell Death in Cancer Therapy
- (2012) Guido Kroemer et al. Annual Review of Immunology
- Comparative Analysis of Tumor-Infiltrating Lymphocytes in a Syngeneic Mouse Model of Oral Cancer
- (2012) Nancy P. Judd et al. OTOLARYNGOLOGY-HEAD AND NECK SURGERY
- Photodynamic therapy of cancer: An update
- (2011) Patrizia Agostinis et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Ectonucleotidases CD39 and CD73 on OvCA cells are potent adenosine-generating enzymes responsible for adenosine receptor 2A-dependent suppression of T cell function and NK cell cytotoxicity
- (2011) Sebastian F. M. Häusler et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- ERK1/2 Regulation of CD44 Modulates Oral Cancer Aggressiveness
- (2011) N. P. Judd et al. CANCER RESEARCH
- Autophagy-Dependent Anticancer Immune Responses Induced by Chemotherapeutic Agents in Mice
- (2011) M. Michaud et al. SCIENCE
- Tumor Cell Death and ATP Release Prime Dendritic Cells and Efficient Anticancer Immunity
- (2010) L. Aymeric et al. CANCER RESEARCH
- Crystal Structure of a Legionella pneumophila Ecto -Triphosphate Diphosphohydrolase, A Structural and Functional Homolog of the Eukaryotic NTPDases
- (2010) Julian P. Vivian et al. STRUCTURE
- Nucleotides released by apoptotic cells act as a find-me signal to promote phagocytic clearance
- (2009) Michael R. Elliott et al. NATURE
- Activation of the NLRP3 inflammasome in dendritic cells induces IL-1β–dependent adaptive immunity against tumors
- (2009) François Ghiringhelli et al. NATURE MEDICINE
- Hydrolysis of extracellular ATP and immune suppression: humans versus mice
- (2008) S. Gorini et al. BLOOD
- Hypoxia-Adenosinergic Immunosuppression: Tumor Protection by T Regulatory Cells and Cancerous Tissue Hypoxia
- (2008) M. V. Sitkovsky et al. CLINICAL CANCER RESEARCH
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started